[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 731
Citations 0
Comment & Response
June 25, 2014

Influence of Chronic Kidney Disease on Warfarin Therapy for Atrial Fibrillation

Author Affiliations
  • 1Department of Medicine, Massachusetts General Hospital, Boston
  • 2Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois
JAMA. 2014;311(24):2541-2542. doi:10.1001/jama.2014.5576

To the Editor Dr Carrero and colleagues1 evaluated the influence of chronic kidney disease (CKD) on the efficacy and safety of warfarin therapy in a population with atrial fibrillation and recent myocardial infarction. Previous studies have found that warfarin, when added to aspirin or dual antiplatelet therapy, is associated with increased risk of major bleeding.2,3 We thus find it surprising that, in this registry-based Swedish investigation, no excess bleeding risk was observed in warfarin users across stages of CKD. Accordingly, the characteristics of the study population deserve careful examination.

First Page Preview View Large
First page PDF preview
First page PDF preview